Skip to main content
Premium Trial:

Request an Annual Quote

For Accelrys, Bookings Up, but Revenues Down in FY 05 Q3

NEW YORK, Jan. 26 (GenomeWeb News) - Accelrys today reported an increase in orders for the third quarter of its 2005 fiscal year, but a decrease in quarterly revenues resulting from a change in its accounting practices.


Accelrys reported total bookings of $37.9 million for the quarter ended Dec. 31, 2004 -- an increase of 9-percent over $34.8 million booked for the same quarter of 2003. Revenues, however, which the company now recognizes on a ratable subscription basis, declined to $22.2 million -- a 30-percent drop from revenues of $31.6 million in the year-ago period.


In line with the change in the company's revenue recognition practice, deferred revenue increased during the quarter, from $29.5 million as of Sept. 30, 2004, to $43.4 million as of Dec. 31, 2004.


The company's quarterly expenses rose to $28.5 million, from $23.5 million in the prior-year period. Accelrys said that $3.3 million of these expenses were associated with its acquisition of SciTegic, which closed in September.


Accelrys spent $4.7 million on R&D during the quarter, a slight increase from $4.6 million in the prior year.


The company posted a quarterly net loss of $5.7 million, compared to $7.9 million in net income that it reported for the comparable period of 2003.


Accelrys held $59.1 million in cash, cash equivalents, restricted cash, and marketable securities as of Dec. 31, 2004.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.